Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
4.720
+0.110 (2.39%)
At close: Mar 9, 2026, 4:00 PM EDT
4.710
-0.010 (-0.21%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Precision BioSciences Employees
Precision BioSciences had 108 employees as of December 31, 2024. The number of employees decreased by 1 or -0.92% compared to the previous year.
Employees
108
Change (1Y)
-1
Growth (1Y)
-0.92%
Revenue / Employee
$10,418
Profits / Employee
-$1,247,791
Market Cap
113.62M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Codexis | 188 |
| Inovio Pharmaceuticals | 134 |
| Fortress Biotech | 101 |
| Korro Bio | 87 |
| Equillium | 35 |
| Oncolytics Biotech | 28 |
| Gain Therapeutics | 25 |
DTIL News
- 9 hours ago - Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - Business Wire
- 7 days ago - Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
- 19 days ago - Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 26 days ago - Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy - Business Wire
- 2 months ago - Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire
- 2 months ago - Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 - Seeking Alpha
- 2 months ago - Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Precision Biosciences: Still Swinging And Finally Drawing Blood - Seeking Alpha